Loss Per Share (GAAP)
$0.02
Revenue
$37.2M
Biotech reports loss. Gyre Therapeutics Inc (NASDAQ: GYRE) reported Q4 2025 GAAP loss of $0.02 per share, missing consensus estimates. The company posted adjusted net income of $4.3 million. Operating income was $0.1 million.
Revenue rises. Q4 revenue reached $37.2 million, up from last year’s revenue of $27.9 million. The company reported cost of revenue of $1.7 million. Management issued fiscal 2026 revenue guidance of $100.5 million to $111 million, implying strong growth versus Q4’s annualized run rate.
What to Watch: Track Q1 2026 revenue momentum when the company next reports to validate whether the $100.5 million floor is conservative or aggressive.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.